Search

Your search keyword '"Wang, Xianding"' showing total 241 results
Start Over Author "Wang, Xianding"
241 results on '"Wang, Xianding"'

1. Risk for Donor-Derived Syphilis after Kidney Transplantation, China, 2007-2022

Author

Yin, Saifu, Wu, Lijuan, Liu, Congke, Jia, Zihao, Wu, Jiapei, Zhang, Fan, Wang, Xianding, Song, Turun, and Lin, Tao

Subjects
China -- Health aspects, Kidneys -- Transplantation, Syphilis -- Risk factors, Organ donors -- Health aspects, Health, Complications and side effects, Risk factors, Health aspects
Abstract

Syphilis transmission remains a public health challenge; [approximately equal to]7.1 million new cases were reported in 2020 (2). Despite its relatively low incidence, if left untreated, syphilis results in substantial [...]

Published
2024
Full Text
View/download PDF

11. Incidence, risk factors, and clinical outcomes of HBV reactivation in non-liver solid organ transplant recipients with resolved HBV infection: A systematic review and meta-analysis

Author

Yin, Saifu, Zhang, Fan, Wu, Jiapei, Lin, Tao, and Wang, Xianding

Subjects
Antiviral agents -- Dosage and administration, Immunotherapy -- Patient outcomes, Hepatitis B -- Risk factors -- Prevention, Liver -- Transplantation, Organ transplant recipients -- Health aspects -- Social aspects, Biological sciences
Abstract

Background Current guidelines do not recommend routine antiviral prophylaxis to prevent hepatitis B virus (HBV) reactivation in non-liver solid organ transplant (SOT) recipients with resolved HBV infection, even in anti-hepatitis B surface antigen (anti-HBs)-negative recipients and those receiving intense immunosuppression. This systematic review and meta-analysis aimed to determine the incidence, risk factors, and clinical outcomes of HBV reactivation in non-liver SOT recipients. Methods and findings Three databases (PubMed, Embase, and Cochrane Library) were systematically searched up to December 31, 2022. Clinical studies reporting HBV reactivation in non-liver SOT recipients were included. Case reports, case series, and cohort studies with a sample size of less than 10 patients were excluded. Random-effects analysis was used for all meta-analyses. We included 2,913 non-liver SOT recipients with resolved HBV infection from 16 retrospective cohort studies in the analysis. The overall HBV reactivation rate was 2.5% (76/2,913; 95% confidence interval [95% CI 1.6%, 3.6%]; I.sup.2 = 55.0%). Higher rates of reactivation were observed in recipients with negative anti-HBs (34/421; 7.8%; 95% CI [5.2%, 10.9%]; I.sup.2 = 36.0%) by pooling 6 studies, experiencing acute rejection (13/266; 5.8%; 95% CI [2.3%, 14.5%]; I.sup.2 = 63.2%) by pooling 3 studies, receiving ABO blood type-incompatible transplantation (8/111; 7.0%; 95% CI [2.9%, 12.7%]; I.sup.2 = 0%) by pooling 3 studies, receiving rituximab (10/133; 7.3%; 95% CI [3.4%, 12.6%]; I.sup.2 = 0%) by pooling 3 studies, and receiving anti-thymocyte immunoglobulin (ATG, 25/504; 4.9%; 95% CI [2.5%, 8.1%]; I.sup.2 = 49.0%) by pooling 4 studies. Among recipients with post-transplant HBV reactivation, 11.0% (7/52; 95% CI [4.0%, 20.8%]; I.sup.2 = 0.3%) developed HBV-related hepatic failure, and 11.0% (7/52; 95% CI [4.0%, 20.8%]; I.sup.2 = 0.3%) had HBV-related death. Negative anti-HBs (crude odds ratio [OR] 5.05; 95% CI [2.83, 9.00]; p < 0.001; I.sup.2 = 0%), ABO blood type-incompatible transplantation (crude OR 2.62; 95% CI [1.05, 6.04]; p = 0.040; I.sup.2 = 0%), history of acute rejection (crude OR 2.37; 95% CI [1.13, 4.97]; p = 0.022; I.sup.2 = 0%), ATG use (crude OR 3.19; 95% CI [1.48, 6.87]; p = 0.003; I.sup.2 = 0%), and rituximab use (crude OR 3.16; 95% CI [1.24, 8.06]; p = 0.016; I.sup.2 = 0%) increased the risk of reactivation. Adjusted analyses reported similar results. Limitations include moderate heterogeneity in the meta-analyses and that most studies were conducted in kidney transplant recipients. Conclusions Non-liver SOT recipients with resolved HBV infection have a high risk of HBV-related hepatic failure and HBV-related death if HBV reactivation occurs. Potential risk factors for HBV reactivation include rituximab use, anti-thymocyte immunoglobulin use, anti-HBs negative status, acute rejection history, and ABO blood type-incompatible transplantation. Further research on monitoring and routine antiviral prophylaxis of non-liver SOT recipients at higher risk of HBV reactivation is required., Author(s): Saifu Yin 1,2, Fan Zhang 1,2, Jiapei Wu 1,2, Tao Lin 1,2,*, Xianding Wang 1,2,* Introduction Hepatitis B virus (HBV) infection is a major public health concern and the [...]

Published
2023
Full Text
View/download PDF

34. Efficacy and safety of stratified versus routine prophylaxis in living kidney transplantation from HBsAg+ donors to HBsAg− recipients: protocol for a multicentre, prospective, observational study

Author

Wang, Xianding, primary, Yin, Saifu, additional, Song, Turun, additional, Huang, Zhongli, additional, Fan, Yu, additional, Liu, Hongtao, additional, Shang, Wenjun, additional, Zhou, Honglan, additional, Li, Xiaohong, additional, and Lin, Tao, additional

Published
2021
Full Text
View/download PDF

46. Prevalence of vitamin D deficiency and impact on clinical outcomes after kidney transplantation: a systematic review and meta-analysis.

Author

Yin, Saifu, Wang, Xianding, Li, Linde, Huang, Zhongli, Fan, Yu, Song, Turun, and Lin, Tao

Subjects
*BACTERIAL disease risk factors, *EVALUATION of medical care, *ONLINE information services, *RELATIVE medical risk, *HYPERURICEMIA, *POLYOMAVIRUS diseases, *GLOMERULAR filtration rate, *META-analysis, *MEDICAL information storage & retrieval systems, *MEDICAL databases, *INFORMATION storage & retrieval systems, *CONFIDENCE intervals, *SYSTEMATIC reviews, *CYTOMEGALOVIRUS diseases, *KIDNEY transplantation, *RESEARCH funding, *DESCRIPTIVE statistics, *DISEASE prevalence, *VITAMIN D deficiency, *MEDLINE, *ODDS ratio, *DATA analysis software, *DISEASE risk factors, *EVALUATION, *DISEASE complications
Abstract

Context The prevalence of vitamin D deficiency (VDD) and its impact on clinical outcomes after kidney transplant (KT) remain poorly defined. Objectives We conducted a meta-analysis to evaluate the impact of early VDD on clinical outcomes after KT. Data Sources Electronic databases (PubMed, Embase, Web of Science, and The Cochrane Library) were systematically searched for eligible publications up to April 30, 2020. Data Extraction Relative risk was presented as hazard ratios (HRs) or odds ratios (ORs) and 95%CIs for dichotomous outcomes. Mean difference (MD) and 95%CIs were presented for continuous outcomes. Results A total of 28 studies (13 prospective and 15 retrospective) were included. VDD was common early after KT, with a prevalence of 52% (95%CI: 41%–64%) at transplant, 34% (95%CI: 17%–51%) at 3 months, and 23% (95%CI: 10%–35%) at 6 months. Early VDD was associated with higher mortality rate after KT (HR, 1.56; 95%CI: 1.32–1.84; P  < 0.001). In addition, early VDD led to higher risk of bacterial infection (OR, 1.82; 95%CI: 1.40–2.36; P  < 0.001), BK polyomavirus infection (OR, 2.11, 95%CI: 1.23–3.61; P  = 0.006), and cytomegalovirus infection (OR, 1.69; 95%CI: 1.24–2.31; P  = 0.001). Early VDD increased the risk of acute rejection as well (HR, 2.28; 95%CI: 1.57–3.30; P  < 0.001). Recipients with early VDD had lower estimated glomerular filtration rates (mean difference: −5.06; 95%CI: −7.28 to 2.83 mL/min; P  < 0.001). Sensitivity analyses showed good stability of the pooled results. Conclusion VDD was common early after KT and associated with higher risk of death and adverse outcomes. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

47. Development and validation of routine clinical laboratory data derived marker-based nomograms for the prediction of 5-year graft survival in kidney transplant recipients

Author

Li, Yamei, primary, Yan, Lin, additional, Li, Yi, additional, Wan, Zhengli, additional, Bai, Yangjuan, additional, Wang, Xianding, additional, Hu, Shumeng, additional, Wu, Xiaojuan, additional, Yang, Cuili, additional, Fan, Jiwen, additional, Xu, Huan, additional, Wang, Lanlan, additional, and Shi, Yunying, additional

Published
2021
Full Text
View/download PDF

48. The Role of CD276 in Cancers

Author

Liu, Shengzhuo, primary, Liang, Jiayu, additional, Liu, Zhihong, additional, Zhang, Chi, additional, Wang, Yang, additional, Watson, Alice Helen, additional, Zhou, Chuan, additional, Zhang, Fan, additional, Wu, Kan, additional, Zhang, Fuxun, additional, Lu, Yiping, additional, and Wang, Xianding, additional

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results